Physician profile
Shadi Hamdeh
NPI 1114350048
$958,811.38
in general payments reported to CMS, 2019-2025
16 companies · $340K in 2025
The $340K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $22.75 · 2021: $8,290 · 2022: $35K · 2023: $156K · 2024: $394K · 2025: $340K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $666K · Travel and Lodging: $143K · Consulting Fee: $42K · Honoraria: $20K · Food and Beverage: $18K · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $666,254.36 |
| Travel and Lodging | $143,273.19 |
| Consulting Fee | $42,171.45 |
| Honoraria | $20,250.00 |
| Food and Beverage | $17,606.04 |
| Education | $473.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242,592.62 | 2019-2025 | |
| Lilly USA, LLC | $201,686.25 | 2022-2025 | Omvoh |
| Janssen Biotech, INC. | $166,878.31 | 2023-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $166,543.76 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $98,609.62 | 2024-2025 | Zymfentra, Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $48,104.10 | 2024-2025 | Entyvio |
| Cook Medical LLC | $25,000.00 | 2019 | |
| Celgene Corporation | $4,296.20 | 2022-2024 | Zeposia |
| Blueprint Medicines Corporation | $2,441.40 | 2024 | Ayvakit |
| Janssen Scientific Affairs, LLC | $2,261.54 | 2019-2023 | Stelara, Tremfya |
| Pfizer INC. | $222.43 | 2019 | |
| Boston Scientific Corporation | $127.48 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.69 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $22.98 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Hamdeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.